肿瘤标志物fPSA的临床应用及其初步评估  

Clinical Use and Primary Evaluation of Tumor Marker-Free Prostate Specific Antigen

作　　者：吴俊渊[1] 高秀英[1] 孔令华[1] 苏平[1] 郭新荣[1] 

机构地区：[1]南通市第一人民医院放免中心,江苏南通226001

出　　处：《标记免疫分析与临床》2002年第1期30-32,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：为对游离前列腺特异性抗原 (fPSA) /总前列腺特异性抗原 (tPSA)比值在临床应用中的价值进行评估 ,本文应用电化学发光免疫测定法 ,检测了 3 8例Pca、68例BPH患者以及 43名无前列腺疾病的正常男子血清tPSA和fPSA含量 ,并计算fPSA/tPA的比值。结果表明单独以血清tPSA大于 4.0 μg/L作为诊断Pca的标准 ,其灵敏度和特异性分别为 84.2 %、75 .0 %。若以血清fPSA/tPSA小于 0 .13作为诊断Pca的限定值 ,当血清tPSA小于 2 .0 μg/L时 ,fPSA/tPSA比值的灵敏度和特异性分别为 10 0 .0 %、5 7.0 % ;当血清tPSA大于 2 0 .0 μg/L时 ,fP SA/tPSA比值的灵敏度和特异性分别为 62 .1%、66.7% ,而当血清tPSA水平在 2 -2 0 μg/L时 ,fPSA/tPSA比值的灵敏度和特异性分别为 93 .6%、89.9%。结果提示fPSA/tPSA比值对tPSA水平在 2 -2 0 μg/L这组人群前列腺癌诊断的准确率可以大大提高 ,而对此以外的人群并无太大价值。Free-prostate specific antigen (fPSA)/total prostate specific antigen(tPSA) ratio was evaluated in clinical utility. Serum tPSA and fPSA level were measured by eletrochemiluminc scence(ECL) immunoassay and fPSA/tPSA ratio was calculated. Samples were drawn from 38 patients with Pca, 68 patients with BPH and 43 health men. Results showed serum tPSA>4.0μg/L as only cut off for diagnosis Pca, sensitity and specificity of fPSA/tPSA ratio were 84.2%, 75.0% respectivity. But fPSA/tPSA ratio<0.13 for diagnosis Pca; they were 100%, 57.0% respectivity when serum tPSA<2.0μg/L;they were 62.1%, 66.7% when serum tPSA>20.0μg/L; they were 93.6%, 89.9% when serum tPSA was 2-20μg/L. fPSA/tPSA ratio may greatly raised accurate rate for diagnoisis prostate cancer when tPSA level between 2-20μg/L and no value to other patients.

关 键 词：前列腺肿瘤 前列腺特异性抗原 肿瘤标志物 FPSA 

分 类 号：R446.6[医药卫生—诊断学]